Clinical Trial Update: Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DASATINIB (Dasatinib)
• Leuprolide (Leuprolide acetate)

Snippet

Sponsor: Noah Hahn, M.D. | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-02-05